BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36322088)

  • 1. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
    Jin L; Zhang Y; Yang W
    Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
    Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
    Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
    Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
    Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Kida K; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Doi T; Oba M; Endo I; Ishikawa T
    Breast Cancer; 2024 May; 31(3):409-416. PubMed ID: 38453739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
    Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
    Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
    BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
    Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
    Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
    Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
    Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
    Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
    J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
    Chen CS; Smith EML; Stringer KA; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2022 Aug; 194(3):551-560. PubMed ID: 35760975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.